H5P Stock Overview
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
Hikma Pharmaceuticals PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£21.20 |
| 52 Week High | UK£25.60 |
| 52 Week Low | UK£19.70 |
| Beta | 0.44 |
| 1 Month Change | -4.50% |
| 3 Month Change | -3.64% |
| 1 Year Change | 6.53% |
| 3 Year Change | -20.30% |
| 5 Year Change | 4.54% |
| Change since IPO | 420.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| H5P | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 1.9% | 2.5% | 1.8% |
| 1Y | 6.5% | -27.7% | 2.2% |
Return vs Industry: H5P exceeded the German Pharmaceuticals industry which returned -27.7% over the past year.
Return vs Market: H5P exceeded the German Market which returned 2.2% over the past year.
Price Volatility
| H5P volatility | |
|---|---|
| H5P Average Weekly Movement | 4.3% |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: H5P has not had significant price volatility in the past 3 months.
Volatility Over Time: H5P's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 9,100 | Riad Mishlawi | www.hikma.com |
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.
Hikma Pharmaceuticals PLC Fundamentals Summary
| H5P fundamental statistics | |
|---|---|
| Market cap | €4.70b |
| Earnings (TTM) | €177.76m |
| Revenue (TTM) | €2.69b |
26.4x
P/E Ratio1.7x
P/S RatioIs H5P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| H5P income statement (TTM) | |
|---|---|
| Revenue | US$2.88b |
| Cost of Revenue | US$1.47b |
| Gross Profit | US$1.41b |
| Other Expenses | US$1.22b |
| Earnings | US$190.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 08, 2024
| Earnings per share (EPS) | 0.86 |
| Gross Margin | 48.94% |
| Net Profit Margin | 6.61% |
| Debt/Equity Ratio | 50.9% |
How did H5P perform over the long term?
See historical performance and comparison